The Phase 3 INTerpath-001 trial readout at ESMO marks the first late-stage success for a personalized mRNA cancer vaccine, though overall survival data are stil

The clearance adds a new functional-cure option for chronic hepatitis B, a virus that has long lacked therapies able to eliminate it.

The approval is a first for an mRNA vaccine against seasonal influenza in the US.

The result is being framed as a watershed for second-line small cell lung cancer, a disease with few durable treatment options.

The clearance gives advanced pancreatic cancer patients a new targeted option across diverse patient groups.

Ivonescimab's momentum has made the PD-1/VEGF bispecific a centerpiece of AstraZeneca's oncology pipeline and of China-origin licensing deals.

The trial signals a shift of in vivo CAR-T development toward autoimmune indications, an area where Korea is seen as lagging on funding.

The readout adds to a crowded field of agents competing in breast cancer settings.

Longer follow-up reinforces Kisqali's role in adjuvant treatment of early breast cancer.

The data support J&J's Halda acquisition and its push into a new prostate cancer drug class.

The totals underscore China's rise as a source of licensed drug assets for global pharma.

AstraZeneca used ESMO to highlight progress across ADCs and lung and gastric cancer programs.

The combination targets a defined MET-driven population after third-generation EGFR inhibitor progression.

The data add Lilly to an increasingly competitive ovarian cancer antibody-drug conjugate field.

The approval extends GSK's PD-1 agent to a new rectal cancer indication.

The disclosure is a setback for an early-phase cell therapy program.

Renewed clinical momentum has lifted biotech shares and drawn investor attention to the sector.

The approval gives Opus a first commercial product and a stated cash runway into 2029.